Cytokinetics (KK3A) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

Cytokinetics DE:KK3A is currently developing the following drugs: Ck-4021586 (150 Mg, 300 Mg, 450 Mg, And 600 Mg), Omecamtiv Mecarbil (Om), Aficamten, Moxifloxacin, Aficamten, Ck-4021586, Aficamten (Ck-3773274) (5 Mg, 10 Mg, 15 Mg And 20 Mg), Metoprolol Succinate (50 Mg, 100 Mg, 150 Mg And 200 Mg), Ck-3828136, Reldesemtiv, Aficamten (5 Mg, 10 Mg, 15 Mg, And 20 Mg), Aficamten (5 - 20 Mg), Ck-3773274, Omecamtiv Mecarbil, Ck-3773274 (5 - 15 Mg), Ck-3773274 (10 - 30 Mg), Moxifloxacin, Omecamtiv Mecarbil (Om), Ck-3773274 - Granules In Capsule, Ck-3773274 - Tablets, Tirasemtiv, Standard of Care, Omecamtiv Mecarbil, 25 Mg Omecamtiv Mecarbil, 37.5 Mg Omecamtiv Mecarbil, 50 Mg Omecamtiv Mecarbil, Reldesemtiv 150 Mg, Reldesemtiv 450 Mg, Omecamtiv Mecarbil Matrix F1 Formulation, Omecamtiv Mecarbil Matrix F2 Formulation, Omecamtiv Mecarbil Swellable Core Technology F2, Ck-2017357, Riluzole, Amg 423, Ck-2017357, Riluzole 50 Mg, Ck-2017357 (Part A), Riluzole 50 Mg (Part B), Ck-2017357 (Part B), 250 Mg Ck-2017357, 500 Mg Ck-2017357, 500 Mg Ck-2017357, 375 Mg Ck-2017357, Ck-1827452 24Mg And 6 Mg Iv Infusion, Ck-1827452 12.5Mg Capsule, Ck-1827452 48 Mg And 11 Mg Iv Infusion, Ck-1827452 25Mg Capsule, Ck-1827452. These drug candidates are in various stages of clinical development as the company works toward FDA approval.